ArticleTranslational andrology and urology2026
Clinical response to firsekibart in a 73-year-old patient with tophaceous gout complicated by prostate cancer and chronic kidney disease: a case report.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The management of acute gout flares in elderly patients with multiple comorbidities remains a significant clinical challenge. Although interleukin-1β (IL-1β) inhibitors are recommended for refractory gout when conventional therapies are unsuitable, evidence remains limited regarding their use in patients with active malignancy and moderate-to-severe renal impairment. This case addresses the knowledge gap in balancing potent anti-inflammatory therapy with complex oncological and renal risks. Case Description: We report a case of a 73-year-old male patient with refractory gout, a disease duration exceeding 20 years, and extensive tophus formation. The patient was concomitantly diagnosed with acinar adenocarcinoma of the prostate, stage 3 chronic kidney disease (CKD), coronary artery disease, and grade 3 hypertension. Due to recurrent acute gout flares, impaired renal function, and a high risk of bleeding, standard anti-inflammatory therapeutic options were contraindicated. After a comprehensive assessment of the potential risks and benefits, treatment was initiated with firsekibart, a novel fully human monoclonal antibody targeting IL-1β, administered as a single 200 mg subcutaneous injection, in combination with a short course of low-dose glucocorticoids. Urate-lowering therapy with febuxostat was subsequently introduced. Marked relief of joint pain and swelling was observed within 24 hours of treatment. During the 3-month follow-up period, inflammatory markers improved substantially, with high-sensitivity C-reactive protein decreasing from 62.36 to 0.9 mg/L. Target serum urate levels were achieved (444.9 µmol/L), and renal function showed improvement, as evidenced by an increase in the estimated glomerular filtration rate from 36.4 to 44.9 mL/min/1.73 m Conclusions: This case suggests that firsekibart may provide rapid and effective inflammation control in high-risk gout populations where standard treatments are limited. These findings highlight the potential of IL-1β targeted therapy as a precision medicine approach for complex patients; however, larger prospective studies are required to validate the long-term oncological and renal safety profile of firsekibart in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.